

Novavax Investor Relations

Novavax today announced that Spain's Public Health Commission (CSP), Italy's Ministry of Health (MoH), and France's Haute Autorité de Santé (HAS) have released updated recommendations expanding use of Nuvaxovid™ (NVX-CoV2373) in their respective countries.

In Spain, the CSP released its autumn/winter [recommendation](#) stating that Nuvaxovid may be used as a booster dose in people aged 18 and older after primary vaccination with mRNA, adenoviral vector, or protein vaccines, regardless of the number of previous booster doses. The CSP recommends a booster dose regardless of the number of doses previously received, at least five months from the last dose administered.

In Italy, the MoH released its [recommendation](#) extending the use of Nuvaxovid in people aged 18 and older as a homologous booster, and as a heterologous booster after primary vaccination with mRNA or adenoviral vector, where use of an mRNA vaccine is not deemed appropriate.

In France, the HAS released its [recommendation](#) for use of Nuvaxovid as a two-dose primary vaccination series in adolescents aged 12 through 17 who have not yet been vaccinated and who do not wish to, or cannot, receive an mRNA vaccine. The decision builds on [existing HAS primary series recommendations](#) in people aged 18 and older, and follows the [recent HAS recommendation](#) of Nuvaxovid as a booster dose for people aged 18 and older who no longer wish to, or cannot, receive mRNA vaccines.

Novavax' COVID-19 vaccine is authorized for use as an adult booster in more than 35 countries, and a number of other countries have policy recommendations allowing use of the vaccine as a booster dose. The vaccine is also authorized for use in adolescents aged 12 through 17 in more than 30 markets around the world, including the [U.S.](#), member states in the [European Union](#), and the [United Kingdom](#). The vaccine is actively under review for both indications in other markets and has ongoing trials to further explore its efficacy and safety.

Trade Name in the U.S.

The trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration.

For more information on the use of Nuvaxovid, please visit:

- [Nuvaxovid \(Spain\)](#)
- [Nuvaxovid \(Italy\)](#)
- [Nuvaxovid \(France\)](#)

<https://ir.novavax.com/Spanish-Italian-and-French-Health-Authorities-Expand-Recommendations-for-Use-of-Novavax-COVID-19-Vaccine>